Enhanced External Counterpulsation is FDA-cleared for heart failure and has been shown in randomized controlled trials to improve exercise capacity, reduce symptoms, and lower key biomarkers of disease severity.
Heart failure affects over 6 million Americans and is one of the leading causes of hospitalization. Despite advances in medications and devices, many patients remain symptomatic — limited by breathlessness, fatigue, and reduced exercise capacity — even on optimal medical therapy.
EECP (Enhanced External Counterpulsation) is FDA-cleared for heart failure and offers a non-invasive, outpatient treatment option that can be used alongside — not instead of — standard heart failure medications. It works by using pneumatic cuffs on the legs to augment blood flow to the heart and reduce the workload of the failing ventricle.
The standard course is 35 one-hour sessions delivered over 7 weeks. Most patients report meaningful improvement in symptoms, exercise tolerance, and quality of life — with benefits that can last 3–5 years after a single course of treatment.
EECP addresses heart failure through five distinct physiological mechanisms, each of which has been studied in clinical research.
EECP deflates the leg cuffs at the moment the heart begins to contract, reducing the resistance the heart must pump against. This "unloading" effect decreases myocardial oxygen demand — particularly valuable in a weakened heart.
Cuff inflation during diastole (the heart's resting phase) drives blood backward toward the coronary arteries, increasing diastolic augmentation. This improves oxygen delivery to the heart muscle itself.
Repeated sessions of EECP stimulate the release of vascular endothelial growth factor (VEGF) and other angiogenic factors, promoting the growth of new blood vessels that bypass blocked or narrowed arteries.
EECP improves the function of the endothelium — the inner lining of blood vessels — by increasing nitric oxide production. Better endothelial function means more flexible, responsive blood vessels and improved cardiac output.
Heart failure is characterized by excessive activation of the sympathetic nervous system and renin-angiotensin system. EECP has been shown to reduce BNP levels and neurohormonal markers, suggesting a direct benefit on the heart failure disease process.
EECP is appropriate for a range of heart failure presentations. Here are the patient populations with the strongest evidence or clinical rationale.
Patients with systolic heart failure (ejection fraction below 40%) who remain symptomatic despite optimal medical therapy. EECP is FDA-cleared for this population and has the strongest evidence base.
Patients with diastolic heart failure (normal or near-normal ejection fraction with symptoms of heart failure). Evidence is more limited but growing, and many EECP providers treat this population.
Patients who have both heart failure and chronic stable angina — a common combination — are strong candidates. EECP is FDA-cleared for both conditions and can address both simultaneously.
Patients who are not eligible for stents or bypass surgery due to diffuse disease, prior failed revascularization, or comorbidities. EECP is specifically recommended by ACC/AHA guidelines for this "no-option" population.
Some EECP centers have used EECP as a bridge therapy for patients awaiting LVAD implantation or cardiac transplantation. This is an off-label use but has been reported in the literature.
EECP is generally well-tolerated, but it is not appropriate for all patients. The following conditions are contraindications or require careful evaluation before treatment:
This list is not exhaustive. Your EECP provider will conduct a full clinical evaluation before beginning treatment. Always consult your cardiologist before starting any new therapy.
EECP for heart failure has been studied in randomized controlled trials, large patient registries, and mechanistic research since the 1990s.
JAMA Internal Medicine
Randomized controlled trial of EECP in heart failure patients with reduced ejection fraction. EECP significantly improved exercise duration and quality of life compared to control at 6 months.
Journal of the American College of Cardiology
Large multicenter registry demonstrating significant reductions in angina frequency and nitroglycerine use in patients with heart failure and coronary artery disease treated with EECP.
Clinical Cardiology
EECP treatment was associated with significant reductions in B-type natriuretic peptide (BNP), a key biomarker of heart failure severity, suggesting a direct hemodynamic benefit.
American College of Cardiology / American Heart Association
EECP is listed as a Class IIb recommendation for patients with refractory angina and heart failure who are not candidates for revascularization, based on evidence of symptom improvement.
For a comprehensive review of EECP clinical evidence across all indications, visit the Clinical Evidence Library →
Use our directory to find verified EECP providers in your state. Our grading system identifies providers who treat heart failure and offer the most comprehensive EECP programs.
Complete overview of the therapy, how it works, and what to expect.
VA coverage, Medicare eligibility, and how veterans can access EECP.
How to travel out of state for a concentrated course of EECP.
Peer-reviewed research on EECP for 20+ conditions.